ARCH, one of life sciences' premier investors, eyes $3B for 13th fund
ARCH Venture Partners plans to raise $3 billion for its 13th fund, per a new SEC filing from this week.
The Chicago-based venture capital firm has been one of the most high-profile backers of life sciences companies for the past few decades and is behind many big names like Illumina, Altos Labs and Vir Biotechnology, among dozens of others.
The firm was the fourth most active investor in private financings last year, per a recent report from investment bank William Blair, having taken part in 18 rounds in 2023. OrbiMed, which unveiled $4.3 billion across three new funds last fall, took first with 24 rounds. Flagship Pioneering, the investor and biotech creator behind the likes of Moderna, is also seeking $3 billion for its next fund, per an SEC filing last November.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.